GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Return-on-Tangible-Equity

Diamyd Medical AB (OSTO:DMYD B) Return-on-Tangible-Equity : -80.48% (As of May. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Diamyd Medical AB's annualized net income for the quarter that ended in May. 2025 was kr-175.53 Mil. Diamyd Medical AB's average shareholder tangible equity for the quarter that ended in May. 2025 was kr218.10 Mil. Therefore, Diamyd Medical AB's annualized Return-on-Tangible-Equity for the quarter that ended in May. 2025 was -80.48%.

The historical rank and industry rank for Diamyd Medical AB's Return-on-Tangible-Equity or its related term are showing as below:

OSTO:DMYD B' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -108.1   Med: -55.99   Max: 45.93
Current: -108.1

During the past 13 years, Diamyd Medical AB's highest Return-on-Tangible-Equity was 45.93%. The lowest was -108.10%. And the median was -55.99%.

OSTO:DMYD B's Return-on-Tangible-Equity is ranked worse than
74.19% of 1267 companies
in the Biotechnology industry
Industry Median: -43.12 vs OSTO:DMYD B: -108.10

Diamyd Medical AB Return-on-Tangible-Equity Historical Data

The historical data trend for Diamyd Medical AB's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Return-on-Tangible-Equity Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.41 45.93 -51.30 -60.49 -96.32

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -85.12 -116.57 -95.79 -134.12 -80.48

Competitive Comparison of Diamyd Medical AB's Return-on-Tangible-Equity

For the Biotechnology subindustry, Diamyd Medical AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Return-on-Tangible-Equity falls into.


;
;

Diamyd Medical AB Return-on-Tangible-Equity Calculation

Diamyd Medical AB's annualized Return-on-Tangible-Equity for the fiscal year that ended in Aug. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Aug. 2024 )  (A: Aug. 2023 )(A: Aug. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Aug. 2024 )  (A: Aug. 2023 )(A: Aug. 2024 )
=-151.85/( (169.397+145.92 )/ 2 )
=-151.85/157.6585
=-96.32 %

Diamyd Medical AB's annualized Return-on-Tangible-Equity for the quarter that ended in May. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: May. 2025 )  (Q: Feb. 2025 )(Q: May. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: May. 2025 )  (Q: Feb. 2025 )(Q: May. 2025 )
=-175.528/( (111.527+324.671)/ 2 )
=-175.528/218.099
=-80.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (May. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Diamyd Medical AB  (OSTO:DMYD B) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Diamyd Medical AB Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines